| Field | Specification |
|---|---|
| Target | |
| Alternative names | Eukaryotic translation initiation factor 4E-binding protein 1; 4E-BP1; eIF4E-binding protein 1; Phosphorylated heat- and acid-stable protein regulated by insulin 1; PHAS-I; EIF4EBP1 |
| UniProt # | |
| Host | |
| Clonality | |
| Isotype | |
| Reactivity | |
| Applications | |
| Immunogen | A synthetic peptide corresponding to a sequence at the C-terminus of human EIF4EBP1, which shares 75% and 81.2% amino acid (aa) sequence identity with mouse and rat EIF4EBP1, respectively. |
| Molecular weight | |
| Purification | |
| Reconstitution | |
| Cellular localization | |
| Concentration | |
| Form | Lyophilized |
| Storage | |
| Catalog no. (Mfr.) | |
| Main SKU |
Product Overview
This rabbit polyclonal antibody targets eukaryotic translation initiation factor 4E-binding protein 1 (gene EIF4EBP1) in human, mouse and rat samples and is validated for Western blot, IHC and flow cytometry. The predicted molecular weight is 12.6 kDa, and the supplier reports an observed band at about 17 kDa.
4E-BP1 (EIF4EBP1) is a translational repressor that binds eIF4E and prevents it from joining eIF4G. When mTORC1 phosphorylates 4E-BP1, it releases eIF4E and cap-dependent translation increases, so phospho-4E-BP1 is a standard readout of mTOR activity.
| Target | Eukaryotic translation initiation factor 4E-binding protein 1 (gene EIF4EBP1; UniProt Q13541, human) |
|---|---|
| Host / Clonality / Isotype | Rabbit / Polyclonal / Rabbit IgG |
| Reactivity | Human, Mouse, Rat |
| Form | Lyophilized |
| Formulation | Per vial: 4 mg trehalose; 0.9 mg NaCl; 0.2 mg Na2HPO4 |
| Calculated MW | 12.6 kDa |
| Observed MW | 17 kDa |
| Storage | As supplied: −20 °C for up to 12 months from receipt. After reconstitution: 4 °C for up to 1 month, or aliquot and keep at −20 °C for up to 6 months. Avoid repeated freeze–thaw cycles. |
Validated Applications
| Western blot | 0.25–0.5 µg/mL (Human, Mouse, Rat) |
|---|---|
| IHC (paraffin sections) | 2–5 µg/mL (Human) |
| Flow cytometry (fixed cells) | 1–3 µg/1×106 cells (Human) |
Samples with a confirmed band (WB): human HEL cells, human PC-3 cells, human HEK293 cells, rat stomach tissue, rat pancreas tissue, mouse pancreas tissue.
Recommended loading (WB): 20–40 µg of total protein per lane.
Conditions in the example images (WB): 5–20% gradient SDS-PAGE under reducing conditions, 30 µg lysate per lane, transfer to nitrocellulose membrane, blocking in 5% non-fat milk, primary antibody at 0.5 µg/mL overnight at 4 °C, HRP-conjugated secondary antibody at 1:5000, ECL detection.
Samples with confirmed staining (IHC): human lung cancer tissue.
Recommended antigen retrieval: heat-mediated, in TE buffer (pH 9.0); citrate buffer (pH 6.0) can be used instead.
Conditions in the example images (IHC): heat-mediated antigen retrieval in EDTA buffer (pH 8.0).
Samples with a confirmed signal (flow cytometry): A431 cells.
Immunogen
Synthetic peptide from the C-terminal region of human EIF4EBP1. Sequence identity with the mouse and rat orthologs: 75% and 81.2%, respectively.
Reactivity Notes
The supplier lists reactivity with human, mouse and rat. UniProt places eukaryotic translation initiation factor 4E-binding protein 1 in the cytoplasm and nucleus. The samples tested by the supplier (listed above) are a practical starting point for positive controls.
Safety
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
Mohanty Suchitra et al. (2017) Multi-targeted therapy of everolimus in Kaposi’s sarcoma associated herpes virus infected primary effusion lymphoma. Apoptosis. 10.1007/s10495-017-1391-1
Yinci Zhang et al. (2019) PKI-587 enhances chemosensitivity of oxaliplatin in hepatocellular carcinoma through suppressing DNA damage repair pathway (NHEJ and HR) and PI3K/AKT/mTOR pathway. American Journal of Translational Research. PMID: 31497229
Yinghai Xie et al. (2021) PKI-587 enhances radiosensitization of hepatocellular carcinoma by inhibiting the PI3K/AKT/mTOR pathways and DNA damage repair. PLoS One. 10.1371/journal.pone.0258817
